Zadaxin thymosin alpha 1: Phase III

In the first part of a 12-week dose-ranging Phase III trial in 31 patients, those receiving 180 ug/week of pegylated interferon alfa-2a plus 0.8 mg, 1.6 mg or 3.2 mg Zadaxin twice weekly had EVR rates...